These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 24189061)

  • 1. Resistance to AFN-1252 arises from missense mutations in Staphylococcus aureus enoyl-acyl carrier protein reductase (FabI).
    Yao J; Maxwell JB; Rock CO
    J Biol Chem; 2013 Dec; 288(51):36261-71. PubMed ID: 24189061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mode of action, in vitro activity, and in vivo efficacy of AFN-1252, a selective antistaphylococcal FabI inhibitor.
    Kaplan N; Albert M; Awrey D; Bardouniotis E; Berman J; Clarke T; Dorsey M; Hafkin B; Ramnauth J; Romanov V; Schmid MB; Thalakada R; Yethon J; Pauls HW
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5865-74. PubMed ID: 22948878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enoyl-Acyl Carrier Protein Reductase I (FabI) Is Essential for the Intracellular Growth of Listeria monocytogenes.
    Yao J; Ericson ME; Frank MW; Rock CO
    Infect Immun; 2016 Dec; 84(12):3597-3607. PubMed ID: 27736774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AFN-1252 is a potent inhibitor of enoyl-ACP reductase from Burkholderia pseudomallei--Crystal structure, mode of action, and biological activity.
    Rao KN; Lakshminarasimhan A; Joseph S; Lekshmi SU; Lau MS; Takhi M; Sreenivas K; Nathan S; Yusof R; Abd Rahman N; Ramachandra M; Antony T; Subramanya H
    Protein Sci; 2015 May; 24(5):832-40. PubMed ID: 25644789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity.
    Karlowsky JA; Kaplan N; Hafkin B; Hoban DJ; Zhanel GG
    Antimicrob Agents Chemother; 2009 Aug; 53(8):3544-8. PubMed ID: 19487444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutations upstream of fabI in triclosan resistant Staphylococcus aureus strains are associated with elevated fabI gene expression.
    Grandgirard D; Furi L; Ciusa ML; Baldassarri L; Knight DR; Morrissey I; Largiadèr CR; Leib SL; Oggioni MR
    BMC Genomics; 2015 Apr; 16(1):345. PubMed ID: 25924916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The enoyl-[acyl-carrier-protein] reductase (FabI) of Escherichia coli, which catalyzes a key regulatory step in fatty acid biosynthesis, accepts NADH and NADPH as cofactors and is inhibited by palmitoyl-CoA.
    Bergler H; Fuchsbichler S; Högenauer G; Turnowsky F
    Eur J Biochem; 1996 Dec; 242(3):689-94. PubMed ID: 9022698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fungal naphtho-γ-pyrones: Potent antibiotics for drug-resistant microbial pathogens.
    He Y; Tian J; Chen X; Sun W; Zhu H; Li Q; Lei L; Yao G; Xue Y; Wang J; Li H; Zhang Y
    Sci Rep; 2016 Apr; 6():24291. PubMed ID: 27063778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triclosan resistance of Pseudomonas aeruginosa PAO1 is due to FabV, a triclosan-resistant enoyl-acyl carrier protein reductase.
    Zhu L; Lin J; Ma J; Cronan JE; Wang H
    Antimicrob Agents Chemother; 2010 Feb; 54(2):689-98. PubMed ID: 19933806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vibrio cholerae FabV defines a new class of enoyl-acyl carrier protein reductase.
    Massengo-Tiassé RP; Cronan JE
    J Biol Chem; 2008 Jan; 283(3):1308-1316. PubMed ID: 18032386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of the Staphylococcus aureus NADPH-dependent enoyl-acyl carrier protein reductase by triclosan and hexachlorophene.
    Heath RJ; Li J; Roland GE; Rock CO
    J Biol Chem; 2000 Feb; 275(7):4654-9. PubMed ID: 10671494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Type II fatty acid synthesis is essential for the replication of Chlamydia trachomatis.
    Yao J; Abdelrahman YM; Robertson RM; Cox JV; Belland RJ; White SW; Rock CO
    J Biol Chem; 2014 Aug; 289(32):22365-76. PubMed ID: 24958721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meleagrin, a new FabI inhibitor from Penicillium chryosogenum with at least one additional mode of action.
    Zheng CJ; Sohn MJ; Lee S; Kim WG
    PLoS One; 2013; 8(11):e78922. PubMed ID: 24312171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perturbation of Staphylococcus aureus gene expression by the enoyl-acyl carrier protein reductase inhibitor AFN-1252.
    Parsons JB; Kukula M; Jackson P; Pulse M; Simecka JW; Valtierra D; Weiss WJ; Kaplan N; Rock CO
    Antimicrob Agents Chemother; 2013 May; 57(5):2182-90. PubMed ID: 23459481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of AFN-1252, a novel FabI inhibitor, against Staphylococcus aureus in an in vitro pharmacodynamic model simulating human pharmacokinetics.
    Tsuji BT; Harigaya Y; Lesse AJ; Forrest A; Ngo D
    J Chemother; 2013 Feb; 25(1):32-5. PubMed ID: 23433442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Efficient and Economical Assay to Screen for Triclosan Binding to FabI.
    Demissie RD; Kabre P; Tuntland ML; Fung LW
    J Biomol Screen; 2016 Apr; 21(4):391-8. PubMed ID: 26538431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of 4-Pyridone derivatives as specific inhibitors of enoyl-acyl carrier protein reductase (FabI) with antibacterial activity against Staphylococcus aureus.
    Takahata S; Iida M; Yoshida T; Kumura K; Kitagawa H; Hoshiko S
    J Antibiot (Tokyo); 2007 Feb; 60(2):123-8. PubMed ID: 17420562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of Exogenous Fatty Acids to Acyl-Acyl Carrier Protein Cannot Bypass FabI Inhibition in Neisseria.
    Yao J; Bruhn DF; Frank MW; Lee RE; Rock CO
    J Biol Chem; 2016 Jan; 291(1):171-81. PubMed ID: 26567338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of API-1252, a novel FabI inhibitor, against clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis.
    Karlowsky JA; Laing NM; Baudry T; Kaplan N; Vaughan D; Hoban DJ; Zhanel GG
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1580-1. PubMed ID: 17220418
    [No Abstract]   [Full Text] [Related]  

  • 20. Characterization of Pseudomonas aeruginosa enoyl-acyl carrier protein reductase (FabI): a target for the antimicrobial triclosan and its role in acylated homoserine lactone synthesis.
    Hoang TT; Schweizer HP
    J Bacteriol; 1999 Sep; 181(17):5489-97. PubMed ID: 10464225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.